NADER EL-MALLAWANY

Concepts (210)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Sarcoma, Kaposi
14
2023
119
6.140
Why?
Epstein-Barr Virus Infections
11
2024
294
3.510
Why?
HIV Infections
16
2023
1889
2.370
Why?
Burkitt Lymphoma
9
2024
144
2.290
Why?
Herpesvirus 4, Human
9
2024
676
2.190
Why?
Herpesvirus 8, Human
3
2023
47
1.660
Why?
Lymphoma
4
2023
322
1.570
Why?
Malawi
17
2025
397
1.380
Why?
Lymphoproliferative Disorders
5
2024
225
1.240
Why?
Lymphoma, Non-Hodgkin
4
2023
163
1.230
Why?
Histiocytosis, Langerhans-Cell
4
2024
224
1.220
Why?
Lymphohistiocytosis, Hemophagocytic
2
2021
145
1.220
Why?
Lymphoma, T-Cell, Peripheral
1
2025
15
0.960
Why?
Child
41
2025
24399
0.940
Why?
Organ Transplantation
2
2024
167
0.920
Why?
Lymphoma, Large B-Cell, Diffuse
3
2024
144
0.810
Why?
Kasabach-Merritt Syndrome
1
2023
16
0.810
Why?
Lymphoma, T-Cell
4
2021
64
0.740
Why?
Antineoplastic Combined Chemotherapy Protocols
8
2024
1252
0.690
Why?
Adolescent
27
2025
19336
0.670
Why?
Interleukin-6
2
2019
419
0.670
Why?
Disease Susceptibility
1
2021
298
0.650
Why?
Anemia
2
2023
339
0.640
Why?
Viral Load
4
2018
383
0.610
Why?
Antiretroviral Therapy, Highly Active
3
2020
267
0.590
Why?
Cytokines
3
2021
1289
0.570
Why?
Herpesviridae Infections
1
2018
142
0.560
Why?
Humans
53
2025
124867
0.520
Why?
Vincristine
5
2020
192
0.510
Why?
Antineoplastic Agents
3
2020
1686
0.450
Why?
Lymphoma, B-Cell
2
2025
141
0.410
Why?
Hematopoietic Stem Cell Transplantation
5
2025
1198
0.390
Why?
Rituximab
3
2024
157
0.390
Why?
Child, Preschool
16
2025
14018
0.390
Why?
Neoplasms
4
2025
2789
0.380
Why?
Methotrexate
3
2025
341
0.380
Why?
Hydroa Vacciniforme
1
2010
3
0.350
Why?
Male
27
2025
61375
0.330
Why?
AIDS-Related Opportunistic Infections
2
2020
136
0.320
Why?
Disease Management
2
2025
525
0.320
Why?
Young Adult
12
2024
9047
0.310
Why?
Female
27
2025
66655
0.300
Why?
Tanzania
3
2023
68
0.290
Why?
T-Lymphocytes, Cytotoxic
1
2010
503
0.280
Why?
Prognosis
6
2025
4631
0.280
Why?
Bone Marrow
3
2021
324
0.270
Why?
Immunotherapy
4
2022
677
0.260
Why?
Prospective Studies
8
2025
6148
0.260
Why?
Neoplasm Staging
3
2019
1278
0.260
Why?
Retrospective Studies
9
2025
16336
0.240
Why?
Laboratories, Hospital
1
2025
20
0.240
Why?
Infant
9
2025
12473
0.240
Why?
Skin Neoplasms
3
2023
872
0.230
Why?
Doxorubicin
3
2020
289
0.220
Why?
Socioeconomic Factors
2
2017
870
0.210
Why?
Antimetabolites, Antineoplastic
1
2025
184
0.210
Why?
Proto-Oncogene Proteins c-bcl-2
1
2024
173
0.210
Why?
Lymphomatoid Papulosis
1
2023
3
0.210
Why?
Cyclophosphamide
3
2020
418
0.210
Why?
Mycosis Fungoides
1
2023
14
0.210
Why?
Treatment Outcome
11
2025
12398
0.210
Why?
HIV-1
2
2016
464
0.200
Why?
Adult
9
2024
29562
0.200
Why?
Mucositis
1
2022
19
0.200
Why?
Morbidity
1
2023
248
0.200
Why?
Haploinsufficiency
1
2024
258
0.200
Why?
Africa South of the Sahara
2
2020
115
0.200
Why?
MAP Kinase Signaling System
1
2024
313
0.200
Why?
Molecular Targeted Therapy
2
2015
361
0.190
Why?
Translocation, Genetic
1
2024
357
0.190
Why?
Medical Oncology
1
2023
214
0.190
Why?
Perforin
1
2021
17
0.190
Why?
Killer Cells, Natural
2
2021
330
0.170
Why?
Virus Replication
1
2023
608
0.170
Why?
T-Lymphocyte Subsets
1
2021
196
0.170
Why?
Cysticercosis
1
2020
22
0.170
Why?
Bleomycin
2
2020
150
0.170
Why?
Pregnancy Complications, Neoplastic
1
2020
62
0.170
Why?
Protein Kinase Inhibitors
1
2024
539
0.160
Why?
Lymphadenopathy
1
2019
30
0.160
Why?
Anthracyclines
2
2017
36
0.160
Why?
Tertiary Healthcare
1
2019
21
0.160
Why?
Clinical Decision-Making
1
2021
266
0.160
Why?
Endemic Diseases
1
2018
56
0.150
Why?
HIV Protease Inhibitors
1
2018
54
0.150
Why?
Anti-HIV Agents
2
2020
316
0.150
Why?
Virus Activation
1
2018
87
0.150
Why?
Biopsy
1
2021
1236
0.140
Why?
Withholding Treatment
1
2017
69
0.140
Why?
Hodgkin Disease
2
2017
292
0.140
Why?
Asia
1
2017
107
0.130
Why?
Plasma
1
2017
98
0.130
Why?
Europe
1
2017
353
0.130
Why?
HIV
1
2017
180
0.130
Why?
Risk
1
2017
754
0.120
Why?
Developing Countries
1
2017
270
0.120
Why?
Remission Induction
1
2016
301
0.120
Why?
Cross-Sectional Studies
1
2023
3435
0.120
Why?
Angiomatosis, Bacillary
1
2014
3
0.120
Why?
Algorithms
1
2021
1624
0.110
Why?
Risk Factors
4
2023
10281
0.110
Why?
Pilot Projects
1
2018
1397
0.110
Why?
T-Lymphocytes
3
2019
1707
0.110
Why?
Mass Spectrometry
1
2014
330
0.110
Why?
Child Health Services
1
2013
86
0.100
Why?
Proto-Oncogene Proteins B-raf
2
2024
188
0.100
Why?
Biomarkers
1
2021
3069
0.100
Why?
Adenoviridae Infections
1
2011
71
0.090
Why?
Neoplasm Recurrence, Local
3
2024
1148
0.090
Why?
Proteomics
1
2014
500
0.090
Why?
Patient-Centered Care
1
2013
224
0.090
Why?
Genetic Predisposition to Disease
1
2021
3152
0.090
Why?
Recurrence
2
2024
1420
0.090
Why?
United States
2
2023
10906
0.080
Why?
Survival Rate
4
2017
2060
0.080
Why?
Infant, Newborn
2
2025
8199
0.080
Why?
DNA, Viral
3
2017
480
0.080
Why?
Genomics
1
2017
1502
0.080
Why?
Clinical Trials as Topic
1
2013
1092
0.080
Why?
Transcriptome
1
2014
953
0.070
Why?
Diagnosis, Differential
2
2024
1884
0.070
Why?
Mutation
1
2021
5845
0.070
Why?
Cell Proliferation
1
2014
2290
0.070
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2014
781
0.070
Why?
Cell Line, Tumor
1
2014
3343
0.070
Why?
Follow-Up Studies
3
2025
5163
0.070
Why?
CD4 Lymphocyte Count
2
2018
231
0.070
Why?
Cell Differentiation
1
2014
1884
0.070
Why?
Prednisone
2
2019
274
0.070
Why?
Time Factors
1
2016
6319
0.060
Why?
Signal Transduction
1
2017
4496
0.060
Why?
Disease-Free Survival
2
2016
899
0.060
Why?
Lymph Nodes
2
2019
381
0.060
Why?
Adenine Nucleotides
1
2024
41
0.060
Why?
Arabinonucleosides
1
2024
32
0.060
Why?
Chromosomes, Human, Pair 8
1
2024
78
0.050
Why?
Drug Monitoring
1
2025
172
0.050
Why?
Chromosomes, Human, Pair 14
1
2024
100
0.050
Why?
Hyperplasia
1
2024
208
0.050
Why?
Biomarkers, Tumor
2
2024
1492
0.050
Why?
DNA Helicases
1
2024
231
0.050
Why?
Salvage Therapy
1
2024
192
0.050
Why?
Transplantation, Autologous
1
2022
298
0.050
Why?
Seroepidemiologic Studies
1
2021
122
0.050
Why?
Stem Cell Transplantation
1
2022
231
0.040
Why?
Creatinine
1
2022
390
0.040
Why?
Transplantation Conditioning
1
2022
324
0.040
Why?
Chromatin
1
2024
550
0.040
Why?
Anticestodal Agents
1
2020
3
0.040
Why?
Praziquantel
1
2020
11
0.040
Why?
Subcutaneous Tissue
1
2020
15
0.040
Why?
Taenia solium
1
2020
11
0.040
Why?
Autoimmunity
1
2021
172
0.040
Why?
Immunity
1
2021
193
0.040
Why?
Albendazole
1
2020
29
0.040
Why?
Paclitaxel
1
2020
130
0.040
Why?
Middle Aged
4
2024
26867
0.040
Why?
Acquired Immunodeficiency Syndrome
1
2020
235
0.040
Why?
Immunocompromised Host
1
2020
293
0.040
Why?
Genetic Association Studies
1
2021
778
0.040
Why?
Nuclear Proteins
1
2024
1265
0.040
Why?
Anti-Retroviral Agents
1
2019
139
0.040
Why?
Proto-Oncogenes
1
2017
34
0.040
Why?
Drug Therapy, Combination
1
2020
1165
0.030
Why?
Antibiotics, Antineoplastic
1
2017
126
0.030
Why?
Viremia
1
2016
127
0.030
Why?
Pregnancy Complications, Infectious
1
2020
450
0.030
Why?
Genetic Testing
1
2021
1002
0.030
Why?
Sialic Acid Binding Ig-like Lectin 2
1
2014
3
0.030
Why?
Antigens, CD20
1
2014
37
0.030
Why?
Risk Assessment
2
2016
3448
0.030
Why?
Antibodies, Monoclonal, Murine-Derived
1
2014
63
0.030
Why?
Transcription Factors
1
2024
2582
0.030
Why?
Central Nervous System Neoplasms
1
2016
196
0.030
Why?
Antigens, CD19
1
2014
178
0.030
Why?
Proportional Hazards Models
1
2017
1358
0.030
Why?
Adoptive Transfer
1
2014
236
0.030
Why?
Botswana
1
2013
76
0.030
Why?
Immune Reconstitution Inflammatory Syndrome
1
2013
18
0.030
Why?
Longitudinal Studies
1
2016
1327
0.030
Why?
Child Nutrition Disorders
1
2013
75
0.030
Why?
Gene Expression
1
2017
1562
0.020
Why?
Mouth Neoplasms
1
2013
84
0.020
Why?
Health Services Accessibility
1
2017
607
0.020
Why?
Sex Factors
1
2016
1286
0.020
Why?
Liver
1
2019
1737
0.020
Why?
Recombinant Fusion Proteins
1
2014
767
0.020
Why?
Thrombocytopenia
1
2013
225
0.020
Why?
Animals
2
2024
34046
0.020
Why?
Incidence
1
2018
3138
0.020
Why?
Japan
1
2011
133
0.020
Why?
Receptors, Antigen, T-Cell
1
2014
483
0.020
Why?
Gene Expression Profiling
1
2017
1705
0.020
Why?
Transplantation, Homologous
1
2011
662
0.020
Why?
Cell Separation
1
2010
226
0.020
Why?
Age Factors
1
2016
2822
0.020
Why?
Kaplan-Meier Estimate
1
2011
1053
0.020
Why?
RNA, Viral
1
2011
538
0.020
Why?
Antibodies, Monoclonal
1
2014
1031
0.020
Why?
In Situ Hybridization, Fluorescence
1
2010
762
0.020
Why?
B-Lymphocytes
1
2011
533
0.020
Why?
Flow Cytometry
1
2010
798
0.020
Why?
Pregnancy
1
2020
7174
0.020
Why?
Graft vs Host Disease
1
2011
541
0.020
Why?
Combined Modality Therapy
1
2011
1240
0.020
Why?
Polymerase Chain Reaction
1
2011
1585
0.020
Why?
Mice
1
2024
17573
0.020
Why?
Chronic Disease
1
2011
1190
0.020
Why?
Immunohistochemistry
1
2010
1691
0.020
Why?
Aged
1
2024
19825
0.020
Why?
EL-MALLAWANY's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (210)
Explore
_
Co-Authors (52)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_